US drug authority approves world's first long-acting HIV regimen

Cabenuva's injectable HIV treatment regimen — which is administered once a month — does not require daily pills

MaxCyte, Inc. (MXCT.L)

LSE - LSE Delayed price. Currency in GBp

Add to watchlist

680.00+10.00 (+1.49%)

At close: 5:08PM GMT

All

Simply Wall St.
What Is The Ownership Structure Like For MaxCyte, Inc. (LON:MXCT)?
The big shareholder groups in MaxCyte, Inc. ( LON:MXCT ) have power over the company. Generally speaking, as a company...
Fool.co.uk
Where I would invest for long-term exposure to disruptive cell-based medicines
When historians look back at 2020, it won’t be the coronavirus crisis that will claim their interest, but the award in October 2020 of the Nobel Prize in Chemistry to two female scientists for their work on the technology of genome editing. Their ‘CRISPR-Cas9’ discovery – which is also known as “genetic scissors” – enables […] The post Where I would invest for long-term exposure to disruptive cell-based medicines appeared first on The Motley Fool UK.
Simply Wall St.
What We Learned About MaxCyte's (LON:MXCT) CEO Compensation
Doug Doerfler became the CEO of MaxCyte, Inc. (LON:MXCT) in 1999, and we think it's a good time to look at the...